11 Recruiting Myelodysplastic Syndromes Phase 1 Clinical Trials
Active phase 1 studies for myelodysplastic syndromes enrolling across the USA. Verify eligibility and contact site coordinators.
All Myelodysplastic Syndromes studiesPhase 1 Studies for Myelodysplastic Syndromes
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Inqovi Maintenance Therapy in Myeloid Neoplasms
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes
📍 West Virginia University Cancer Institute — Morgantown, West Virginia
View Study & Checklist ➔5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
📍 Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
📍 Mayo Clinic — Jacksonville, Florida
View Study & Checklist ➔Study of REM-422 in Patients With AML or Higher Risk MDS
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
📍 H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
View Study & Checklist ➔Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔